Loading stock data…
Jaguar Health, Inc. (JAGX)
$0.41-0.18 (-30.60%)
Market ClosedLast close Sep 8
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jaguar Health, Inc. in the Healthcare sector is trading at $0.41 with a market capitalization of $2M. The stock is currently near its 52-week low of $0.40, remaining 97.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.25M↑ | $3.23M↑ | $3.08M↑ | $2.98M↑ | $2.21M |
| Gross Profit | $19.09M↑ | $1.03M↓ | $2.55M↑ | $2.45M↑ | $1.70M |
| Operating Income | $10.18M↑ | -$20.44M↓ | -$7.24M↑ | -$8.01M↑ | -$9.42M |
| Net Income | $8.85M↑ | -$23.06M↓ | -$9.50M↑ | -$10.41M↑ | -$10.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The com...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
240.66%
Volume
Today's trading volume
949,782
Recent News
Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise
The non-prescription digestive-support product extends Jaguar Health’s Neonorm franchise into the companion-animal market, with additional online and retail distribution expected shortly. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) has launched Neonorm Dog on Amazon as part of the commercial rollout of its new non-prescription animal-health product.
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ...
Jaguar Health Inc (JAGX) reports groundbreaking MVID trial results and secures $18M in non-dilutive capital via FuturePak deal, despite a 60% revenue decline.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.9% and
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Jaguar Health Inc (JAGX) reports an 816% revenue increase, driven by strategic out-licensing and promising clinical advancements.
Jaguar Health (JAGX) Q3 2025 Earnings Transcript
Need a quote from a Motley Fool analyst? Before I turn the call over to management, I'd like to remind you that management make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, product initiatives, including products in the development stage, which may achieve scientific objectives or meet stringent regulatory requirements.